Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DCL000109

Drug Information
NameEnzastaurin
Synonyms3-(1-methylindol-3-yl)-4-[1-[1-(pyridin-2-ylmethyl)piperidin-4-yl]indol-3-yl]pyrrole-2,5-dione; CHEMBL300138; UNII-UC96G28EQF; 1H-Pyrrole-2,5-dione, 3-(1-methyl-1H-indol-3-yl)-4-(1-(1-(2-pyridinylmethyl)-4-piperidinyl)-1H-indol-3-yl)-; 170364-57-5; LY317615; 3-(1-methyl-1H-indol-3-yl)-4-{1-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1H-indol-3-yl}-1H-pyrrole-2,5-dione; AC-5900; CID176167; AC1L41YQ; LY317615, Enzastaurin; LE-0014; S1055_Selleck; CHEBI:183217; Enzastaurin
CompanyEli Lilly
IndicationBrain and Central Nervous System Tumors
[ICD9: 191   ICD10: C71]
Phase I    [1]
Glioblastoma Multiforme
[ICD9: 191   ICD10: C71]
Phase II    [1]
Non Hodgkin Lymphoma
[ICD9: 200, 202   ICD10: C82-C85]
Phase III    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C32H29N5O2/c1-35-19-25(23-9-2-4-11-27(23)35)29-30(32(39)34-31(
29)38)26-20-37(28-12-5-3-10-24(26)28)22-13-16-36(17-14-22)18-21-8
-6-7-15-33-21/h2-12,15,19-20,22H,13-14,16-18H2,1H3,(H,34,38,39)
InChIKeyAXRCEOKUDYDWLF-UHFFFAOYSA-N
Canonical SMILESCN1C=C(C2=CC=CC=C21)C3=C(C(=O)NC3=O)C4=CN(C5=CC=CC=C54)C6CCN(CC6)CC7=CC=
CC=N7    
Therapeutic ClassAntineoplastic Agents
CAS NumberCAS 170364-57-5
PubChem Compound IDCID 176167.
PubChem Substance IDSID 3891570.
ClinicalTrials.govNCT00332202;
NCT00438997;
NCT00509821;
TargetGlycogen synthase kinase-3 beta Inhibitor[2][3]
Glycogen synthase kinase-3 beta Multitarget[2][3]
Protein kinase BInhibitor[2][3]
Protein kinase BMultitarget[2][3]
Protein kinase C beta typeInhibitor[2][3]
Protein kinase C beta typeMultitarget[2][3]
Ref 1Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. To Reference
Ref 2Enzastaurin shows preclinical antitumor activity against human transitional cell carcinoma and enhances the activity of gemcitabine. Mol Cancer Ther. 2009 Jul;8(7):1772-8. Epub 2009 Jun 9. To Reference
Ref 3A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543